公开(公告)号：EP1945197A4

公开(公告)日：2010-08-11

申请号：EP06790888

申请日：2006-10-24

申请人： ORBUS PHARMA INC

发明人： JOSHI LAXMINARAYAN ,  LEFLER ROBERT SCOTT

IPC分类号： A61K31/138 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K47/30

CPC分类号： A61K31/138 ,  A61K9/1635 ,  A61K9/2077

公开(公告)号：EP1871396A4

公开(公告)日：2009-07-15

申请号：EP06721755

申请日：2006-04-05

申请人： ORBUS PHARMA INC

发明人： LAXMINARAYAN JOSHI

IPC分类号： A61K31/724 ,  A61K9/48 ,  A61K31/404 ,  A61K47/26 ,  A61P3/06

CPC分类号： C08B37/0015 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/404 ,  A61K31/724 ,  A61K47/6951 ,  B82Y5/00

公开(公告)号：EP1981494A1

公开(公告)日：2008-10-22

申请号：EP06705097.1

申请日：2006-02-02

申请人： Orbus Pharma Inc.

发明人： LAXMINARAYAN, Joshi

IPC分类号： A61K31/40 ,  A61K9/20 ,  A61K47/40 ,  A61K9/16 ,  A61P3/06

CPC分类号： A61K9/2013 ,  A61K9/2018 ,  A61K9/205 ,  A61K31/40 ,  A61K47/6951 ,  B82Y5/00

摘要： The present invention is a new stable drug composition particularly suitable for use as an antihypercholesterolaemic or antihyperlipidaemic agent. The present invention is specifically a drug composition comprising a pharmaceutical, a complexing agent and a surfactant, and a method for manufacturing same. When applied to unstable drugs with low solubility and poor bioavailability, like HMG-CoA reductase inhibitors and especially atorvastatin calcium amorphous form, the resulting drug composition is more stable and is characterized by an improved dissolution profile.

公开(公告)号：EP1342470B1

公开(公告)日：2007-08-15

申请号：EP02386005.9

申请日：2002-03-04

申请人： Orbus Pharma Inc.

发明人： Karavas, Evangelos ,  Kotzagiorgis, Evangelos

IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/545

CPC分类号： A61K31/545 ,  A61K9/0007 ,  A61K9/2027 ,  A61K9/284 ,  A61K9/2853

公开(公告)号：EP1945197A1

公开(公告)日：2008-07-23

申请号：EP06790888.9

申请日：2006-10-24

申请人： Orbus Pharma Inc.

发明人： JOSHI, Laxminarayan ,  LEFLER, Robert, Scott

IPC分类号： A61K31/138 ,  A61K47/30 ,  A61K9/28

CPC分类号： A61K31/138 ,  A61K9/1635 ,  A61K9/2077

摘要： The present invention is a new stable extended release drug composition particularly suitable for use as a beta-adrenoreceptor antagonist agent. The present invention is specifically a drug composition comprising a pharmaceutical, a methacrylic acid copolymer and a matrix forming agent, and a method for manufacturing same. When applied to highly soluble drugs like metoprolol succinate, the resulting drug composition is characterized by an extended-release profile.

公开(公告)号：EP1871396A1

公开(公告)日：2008-01-02

申请号：EP06721755.4

申请日：2006-04-05

申请人： Orbus Pharma Inc.

发明人： LAXMINARAYAN, Joshi

IPC分类号： A61K31/724 ,  A61P3/06 ,  A61K31/404 ,  A61K9/48

CPC分类号： C08B37/0015 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/404 ,  A61K31/724 ,  A61K47/6951 ,  B82Y5/00

摘要： The present invention relates to pharmaceutical compositions containing an HMG-CoA reductase inhibitor which is protected from destabilization in acidic environments by utilizing cyclodextrin as an inclusion complexing agent. The present invention further relates to the preparation of inclusion complexes of HMG-CoA and cyclodextrin and to their use in the treatment of hypercholesterolemia and hyperlipidemia.

摘要翻译： 本发明涉及含有HMG-CoA还原酶抑制剂的药物组合物，其通过利用环糊精作为包合络合剂而在酸性环境中被保护免于不稳定。 本发明进一步涉及HMG-CoA和环糊精包合络合物的制备及其在治疗高胆固醇血症和高脂血症中的用途。

公开(公告)号：EP1940391A4

公开(公告)日：2010-01-20

申请号：EP05807932

申请日：2005-11-10

申请人： ORBUS PHARMA INC

发明人： LAXMINARAYAN JOSHI

IPC分类号： A61K31/404 ,  A61K9/20 ,  A61K47/34 ,  A61K47/40 ,  A61P3/06

CPC分类号： A61K9/2077 ,  A61K9/1652 ,  A61K9/2027 ,  A61K31/404 ,  A61K47/6951 ,  B82Y5/00

公开(公告)号：EP1940391A1

公开(公告)日：2008-07-09

申请号：EP05807932.8

申请日：2005-11-10

申请人： Orbus Pharma Inc.

发明人： LAXMINARAYAN, Joshi

IPC分类号： A61K31/404 ,  A61P3/06 ,  A61K47/40 ,  A61K47/34 ,  A61K9/20

CPC分类号： A61K9/2077 ,  A61K9/1652 ,  A61K9/2027 ,  A61K31/404 ,  A61K47/6951 ,  B82Y5/00

摘要： The present invention is a new stable extended release drug composition particularly suitable for use as an antihypercholesterolaemic or antihyperlipidaemic agent. The present invention is specifically a drug composition comprising a pharmaceutical, a complexing agent and a matrix-forming agent, and a method for manufacturing same. When applied to acid-labile drugs like HMG-CoA reductase inhibitors, the resulting drug composition is stabilized and is characterized by an extended-release profile.